Pirespa pirfenidone regulatory update

FDA's Pulmonary-Allergy Drug Advisory Committee will meet on March 9 to discuss an NDA from InterMune for pirfenidone to treat idiopathic pulmonary fibrosis (IPF). The oral p38 mitogen-activated prot...